Ana Gallego-Lleyda - Concepedia

Author

Ana Gallego-Lleyda

Universidad de Zaragoza

Also Known As

A. Gallego-Lleyda, Ana Gallego-Lleyda

Publications

539

Citations

H-Index

Concepts

All Affiliations

Universidad de Zaragoza Instituto de Nanociencia y Materiales de Aragón Instituto de Investigación Sanitaria Aragón Hospital Clínico Universitario Lozano Blesa Hospital Universitario Miguel Servet

About

Ana Gallego-Lleyda is an author at Universidad de Zaragoza specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	177
2	Cell Biology	4	4	122
3	Immunology	3	3	103
4	Engineering	2	2	74
5	Biomolecular Engineering	2	2	74

Ana Gallego-Lleyda

Publications

280

Citations

H-Index

Page 1

	Year	Citations
High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer Diego de Miguel, Ana Gallego-Lleyda, José M. Ayuso, Cancer Letters NanomedicineNanotherapeuticsEngineeringPolymer-drug ConjugateMedicine	2016	55
Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein Alberto Bosque, Lisa Dietz, Ana Gallego-Lleyda, Oncotarget	2016	52
Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells Diego de Miguel, Ana Gallego-Lleyda, Alberto Anel, Leukemia Research Disc RecruitmentCell TraffickingCell InteractionImmunologyCell-matrix Interaction	2015	50
TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells Diego de Miguel, Ana Gallego-Lleyda, José M. Ayuso, Nanotechnology	2016	39
Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells Diego de Miguel, Ana Gallego-Lleyda, Patricia Galán‐Malo, Clinical & Translational Oncology Leukemic CellsApoptosisImmunologyCell DeathImmunologic Mechanism	2015	31
Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma Ana Gallego-Lleyda, Diego de Miguel, Alberto Anel, International Journal of Molecular Sciences ImmunologyTumor BiologyNanomedicineOncologyTherapeutic Nanomaterials	2018	22
Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential Diego de Miguel, Ana Gallego-Lleyda, Miguel Martinez-Ara, Cancers NanoparticlesEngineeringChemoprevention StrategyExtracellular MicrovesiclesTumor Biology	2019	19
Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells Diego de Miguel, Ana Gallego-Lleyda, José M. Ayuso, Recent Patents on Anti-Cancer Drug Discovery	2016	12

Page 1